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Hypofractionated radiotherapy for breast cancer
acceleration of the START A treatment regime:
intermediate tolerance and efficacy
Stefan Janssen, Christoph Glanzmann, Stephanie Lang, Sarah Verlaan, Tino Streller, Doris Wisler,
Claudia Linsenmeier and Gabriela Studer*
Abstract
Purpose: Prospective evaluation of accelerated hypofractionated radiotherapy (RT) in breast cancer patients treated
with 41.6 Gy in 13 fractions plus boost delivered five times a week.
Patients and methods: Between 03/2009 and 10/2012 98 consecutive patients aged >55 years presenting with
breast cancer (invasive cancer: n = 95, ductal carcinoma in situ (DCIS): n = 3) after breast conserving surgery were
treated in our institution with the following schedule: 41.6 Gy in 13 fractions 4 times a week and 9 or 12 Gy boost
in 3 or 4 fractions (on day 5 each week), cumulative dose: 50.6 Gy in 3.2 weeks or 53.6 Gy in 3.4 weeks, respectively
depending on resection status. 56 patients had a T1 tumor, 39 a T2 tumor. N-status was as follows: N0: n = 71, N1:
n = 25, N2/3: n = 2. 23 patients (24%) received chemotherapy before RT. A prospectively planned follow-up (FU) visit
with objective and subjective assessment of treatment tolerance (questionnaires) was performed 0 and 8 weeks
after RT completion, and one, two and four years later, respectively.
Results: Mean/median follow-up was 32/28 months (range: 12-56). After 2 years local control, loco-regional control
and disease-free survival was 100%, 100%, and 98%, respectively. Overall survival was 96% at 2 years. Cosmetic
outcome was very good with patients being satisfied or very satisfied in 99% (n = 86/87), 97% (n = 55/57) and
100% (n = 25/25) after one, two and four years after RT, respectively. No grade ≥ 2 pain was described in the 25
patients with a FU of at least 4 years. Fibrosis, telangiectasia and edema were found in 7-15%, 0-22% and 0-11% at
one, two, and four years, respectively, and are comparable to other trials.
Conclusion: The applied hypofractionated RT regime with single doses of 3.2 Gy plus boost doses of 9-12 Gy in 3–4
fractions applied in 5 sessions a week was effective and well tolerated on intermediate term FU.
Introduction
Radiotherapy is the standard treatment after breast con-
serving surgery reducing the risk of local failure and im-
proving overall survival in patients with breast cancer
[1-4]. The most common fractionation schedule is 50 Gy
in 25 fractions delivered over five weeks [5]. In the past
years four large randomized hypofractionation trials with
up to 10 years follow-up data showed equal results in
terms of outcome and toxicity compared to the standard
regime (Table 1) [6-10]. The Canadian trial and START
B trial used a pragmatic regime of 42.5 Gy and 40.05 Gy
in 16 or 15 fractions of 2.66 and 2.67 Gy, respectively.
This was delivered five times a week adding up to about
3 weeks of therapy. In START A trial prescription dose
of 39 Gy/41.6 Gy in 13 fractions 3×/week (single dose:
3/3.2 Gy) was applied in 5 weeks in order to keep the
total treatment time comparable with the standard arm
of 50 Gy in 5 weeks. The recurrence rate for the patients
treated with 39 Gy in 13 fractions was slightly higher
however not statistically significant compared to the
control group. The experimental arms of START A and
B have not been tested against each other in randomized
trials. The START B regime holds the advantage of a
short treatment time of 3 weeks.
Here we present results of our prospective single insti-
tution experience treating breast cancer patients with an
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accelerated hypofractionated schedule with 41.6 Gy in
13 fractions 5 times a week and an additional boost in
less than three and a half weeks.
Methods
From 03/2009-10/2012 95 patients older than 55 years
with invasive breast cancer and 3 patients with ductal
carcinoma in situ (DCIS) were postoperatively treated in
our institution with the following schedule:
For R0 resection: 41.6 Gy in 13 fractions 4 times a week
and 9 Gy boost in 3 fractions (on day 5 each week), cumu-
lative dose: 50.6 Gy in 3.2 weeks.
For R1 resection: 41.6 Gy in 13 fractions 4 times a week
and 12 Gy boost in 4 fractions (on day 5 each week, after-
wards daily), cumulative dose: 53.6 Gy in 3.4 weeks.
In the beginning of this RT regime in our institution in
2009 boost was carried out with 5-10×2 Gy (n = 10 in-
cluded in this study) and three patients younger than
55 years were included (45 years: n = 2, 48 years: n = 1). In
three patients an additional radiotherapy of periclavicular
lymphatic drainage was carried out. 23 patients (24%) re-
ceived chemotherapy before RT which in majority consisted
of 4 courses of AC (adriamycin and cyclophosphamide) and
12 courses of taxol. Patient related parameters are summa-
rized in Table 2.
Treatment planning was performed on CT datasets in
Pinnacle treatment planning system using a 3-D con-
formal technique. All patients were treated in supine
position using two to four tangential fields. Dose was
prescribed to the PTV and was maintained between-5
and +7% of the reference dose according to the ICRU
50/62 report. In boost regions hot spots of >105% were
avoided if possible.
In 90 patients boost was delivered with electrons
(6-16 MeV). In 8 patients a photon boost was applied
due to anatomical circumstances and larger volume. In
recent patients RT concept was switched to 39.9 Gy
in 15 fractions if a photon boost was indicated. In 30
patients (31%) a bolus material was used (0.5-1 cm) for
treating the boost volume to optimize dose distribution
at depth.
Exclusion criteria for this study were: Multicentric le-
sions or required boost volume exceeding one breast
volume quadrant. In these cases a schedule with conven-
tional fractionation was applied. Patients < 55 years were
treated according to START B trial with 39.9 Gy in 15
fractions (reported elsewhere).
Acute toxicity was assessed weekly during treatment,
at the end of therapy and 8 weeks later. Prospectively
planned follow up (FU) visits with objective and subject-
ive assessment of treatment tolerance (questionnaires)
were performed one (n = 74), two (n = 57) and four years
(n = 25) post radiation, respectively. Acute and late tox-
icity was assessed according to Common Terminology
Criteria for Adverse Events (CTCAE) version 4.
Statistical analysis
Survival analyses were performed using SPSS version 21.
Ordinal and binary logistic regression analyses were car-
ried out using commercially available Minitab software
version 16.2.4.3. A p-value of less than 0.05 was consid-
ered as statistically significant.
Table 1 Literature review: randomized studies with different hypofractionation schedules in breast cancer patients,
LR = local recurrence, CTx = chemotherapy, RT ln = periclavicular radiotherapy of lymph nodes, *not randomized
Study Pat. FU
(yrs)
Prescription dose
in Gy (weeks)
LR Induration Teleangiectasia Breast
edema
Excellent or
good cosmetic
outcome
CTX RT
ln
Boost
Whelan “Ontario
Trial” (2010) [7]
1234 10 25×2 = 50 6,7% 10.4% 71.3% 11% 0% 0%
16×2,66 = 42,5 (3) 6,2% 11.9% 69.8%
Yarnold (2005) 1410 10 25×2 = 50 12,1% 28.6% 13.8% 12.6% 14% 21% 75%
Owen (2006) [9]
“START Pilot study”
13×3,3 = 42,9 (5) 40.8% 14.3% 20.3% (7×2 = 14 Gy)
13×3,0 = 39 (5) 9,6% 20.4% 8.6% 10.8%
14,8%
START A (2013) [8] 2236 10 25×2 = 50 6.7% 27.1% 7.2% 13.5% 35% 14% 61%
13×3,2 = 41,6 (5) 5.6% 28.2% 7.1% 11.8% (5×2 = 10 Gy)
13×3,0 = 39 (5) 8.1% 21.6% 3.0% 7.3%
START B (2013) [8] 2215 10 25×2 = 50 5.2% 17.4% 5.8% 9.0% 22% 7% 43%
15×2,67 = 40 (3) 3.8% 14.3% 4.2% 5.1% (5×2 = 10 Gy)
Kim (2013)* [12] 276 5 13×3 = 39 (3.2) 1.4% 3% (1y)
2% (2y)
20.4% (1y)
3% (2y)
83% 74% 0% 100% (3×3 = 9 Gy)
Present study* 98 3 13×3.2 = 41.6(3.2) 0% 15% (1y)
7% (2y)
6% (1y)
22% (2y)
11% (1y)
0% (2y)
99% (1y)
97% (2y)
24% 3% 99% (3×3 = 9 Gy)
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Results
Disease control
Mean/median follow-up time was 32/28 months (range:
12-56). No local or loco-regional recurrence was ob-
served. After 2 years local control, loco-regional control
and disease-free survival was 100%, 100%, and 98%, re-
spectively. Overall survival was 96%. At time of analysis
4 patients were dead after 25/30/42/52 months of FU: two
of them due to distant metastases (meningiosis n = 1, dis-
seminated metastases n = 1), two patients died from non-
breast cancer related causes (pulmonary embolism n = 1,
second primary in the lung with distant metastases n = 1).
Early side effects
Grade 1 acute skin toxicity was observed in 80% (grade 2:
5%) directly after RT and in 23% after 8 weeks. Edema of
the breast was seen in 7% before start of RT and in 13%
and 10% immediately after RT completion and after 8
weeks, respectively. Pain within the treated breast was re-
ported before RT start in 11% (grade 1: 5%, grade 2: 6%)
and in 28% (grade 1: 11%, ≥ grade 2: 17%) and 15% (grade
1: 8%, ≥ grade 2: 7%) directly after RT and 8 weeks later,
respectively (Figure 1A-C).
Late term effects - objective late tolerance
Edema of the breast was observed in 11% (8/66), 20%
(11/45) and 0% (0/23) after one, two and four years, re-
spectively (Figure 1C). Hyperpigmentation of the whole
breast (and boost region) was observed in 23% (30%),
19% (25%) and 16% (22%) after one, two and four years,
respectively (Figure 1D). Telangiectasia of the irradiated
breast (and boost region) was present in 0% (6%), 6%
(19%) and 22% (22%), fibrosis in 15% (25%), 7% (20%)
and 13% (20%) after one, two and four years, respectively
(Figure 1E + F).
Late term effects - subjective satisfaction
Patients were satisfied or very satisfied in 99%, 97% and
100% after one, two and four years, respectively (Figure 1G).
One year after RT completion 13% (13/89) of the pa-
tients complained about pain (grade 1: 9%, ≥ grade 2:
4%). After two and four years pain was assessed in 15%
(8/57) (grade 1: 11%, ≥ grade 2: 4%) and 8% (2/25), re-
spectively (Figure 1A). No grade 2 pain or more was
described after four years and no pain grade 5 or higher
was observed in the entire FU period (except for three
patients directly after RT completion).
Predictive value of early symptoms on later tolerance
4/14 patients complaining about pain before RT start
had persistence during further treatment. Pain status be-
fore and after RT/8 weeks later did not correlate with
presence of pain in further FU period. Also edema of the
breast immediately after RT did not correlate with its
persistence during FU.
Volumetric results
The mean volume of the breast was 682ccm (range: 258-
1612). The mean volume of the boost region was 100ccm
(range: 20-328). Additionally we assessed the volume of
105%, 110% and 115% isodoses outside the boost planning
Table 2 Treatment and patient related parameters
Mean age (years) 69 (range: 45-92)
RT prescription dose 13 × 3.2 = 41.6 Gy
RT boost doses
no boost 1
1 × 3 = 3 Gy 1
3 × 3 = 9 Gy 65
4 × 3 = 12 Gy 23
5 × 2 = 10 Gy 2
8 × 2 = 16 Gy 2
10 × 2 = 20 Gy 4
RT periclavicular lymphatics
N-status 3
N0 71
N1 25
N2 1
N3 1
T-status
DCIS 3
T1 56
T2 39
T3 0
T4 0
Grading
G1 16
G2 45
G3 33
Not known 4
R0 11
R1 87
Hormone receptor
Positive 85
Negative 12
Not known 1
Her2 status
Positive 10
Negative 86
Not known 2
Chemotherapy 23
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target volume (PTV). The mean volume of 43.7 Gy (105%),
45.8 Gy (110%), and 47.8 Gy (115%) isodose was 161ccm
(range: 0-1349), 78ccm (range: 1-815), and 48ccm (range:
0-522), respectively.
No continuous correlation in logistic regression ana-
lyses was found in acute and late toxicity and dose-
volume parameters like breast- and boost volume, boost
dose or different isodose levels.
Discussion
Our goal was to assess tumor control and treatment toler-
ance of accelerated hypofractionated RT with 3.2 Gy single
A  Pain assessment (pain scale 1-10)
B  Acute skin toxicity (grade 1-3)
C  Edema
D  Pigmentation
E  Teleangiectasia
F  Fibrosis
G  Overall treatment satisfaction
Figure 1 A- G: Acute and intermediate toxicity and overall treatment satisfaction. A: Pain assessment (pain scale 1-10). B: Acute skin toxicity.
C: Edema. D: Pigmentation. E: Teleangiectasia. F: Fibrosis. G: Overall treatment satisfaction.
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doses and sequential margin-adapted hypofractionated
boost in breast cancer patients. After a mean FU of almost
three years patient were highly satisfied with cosmetic out-
comes, the rate of late sequels was comparable to pub-
lished data (Table 1) [6-9]. Limitations of our study are
the limited number of patients and the relatively short FU.
This also aggravates the logistic regression analyses after 4
years with a limited number of patients.
Institutional development of hypofractionation schedules
in breast cancer
Between 1967 and 1978 nearly all patients with post-
mastectomy RT were treated with a hypofractionated re-
gime (42.9 Gy in 10-13 fractions of 3.3 Gy 3×/week plus
boost of 9.9 Gy/3 fractions), and a large part of patients
with head and neck cancer received between 15 - 16
fractions of 3.3 Gy target dose, with a tolerance compar-
able to conventional fractionation. This regime has been
abandoned after publication of a preliminary FU of a
large fractionation trial [11] in favor of standard frac-
tionation in a subgroup of 'glottic mobile'. Beginning in
1994, we used a hypofractionated regime in older pa-
tients (> 70 years) applying a whole breast dose of 45-
48 Gy in 12-13 fractions of 3.0 Gy with excellent tolerance
(unpublished results). After publication of the START
trial in 2008, we decided to change our treatment regime
in breast cancer based on the trial results in all patients.
Late term tolerance
In hypofractionation late tissue tolerance is a major con-
cern. We judged late reactions one, two and four years
after RT completion using standardized questionnaires.
In terms of fibrosis and edema our results were compar-
able to the four randomized trials. We found slightly
more telangiectasia in the irradiated breast and boost re-
gion. This could be explained by the consistent use of
boost in contrast to the above mentioned randomized
trials where boost was applied in only 0-75% [6,7,9,10].
Patients judged cosmetic results as very satisfying or
satisfying in 99%, 97% and 100% after one, two and four
years, respectively. This compares favorably to the out-
come of Kim et al. and Whelan et al. with 70% and 83%,
respectively ([7,12] Table 1).
Patients with early pain/enhanced skin reaction before
or directly after RT did not show to have any increased
consecutive risk for pain or skin reactions in the future,
however, the sample size at two and four years and the
number of events is still too small to draw reliable con-
clusions from it.
Early side effects
Acute side effects were assessed directly after RT and eight
weeks later. After 8 weeks acute skin toxicity grade 1,
edema of the breast and pain were present in 23%, 10%,
and 15%, respectively. No grade 3 acute toxicity was ob-
served. These results compare favorable to the results of
Kim et al. assessing toxicity after RT at similar time points.
The above mentioned randomized trials mainly focused
on late tissue effects [6-9].
Boost in hypofractionated schedules
The results of the START trials induced us to return to
our formerly used hypofractionation regime in breast
treatment. We changed our former regime to 5 fractions/
week, as there is much evidence of increased efficacy
while comparable tolerance applying such a dose re-
gime with 5 instead of 3 fractions/week. Whole breast
irradiation was carried out 4 times a week; additionally,
we applied a margin-directed boost of 9 - 12 Gy in 3-4
fractions on day 5 of each week shown to be effective in
conventional fractionation [13]. In contrast to the above
mentioned randomized trials in which no boost [7] or a
conventional fractionated boost of 5-7× 2.0 Gy = 10-14 Gy
was applied in 43-75% of all cases [8,9], we applied a
hypofractionated boost as described by Liau et al. and
other study groups to further shorten overall treatment
time [12,14-16]. Outcome was satisfactory with 100% local
and loco-regional control and very satisfying or satisfying
cosmesis in 100% at mean/median 32/38 months. These
results stand in line with a recently published phase 2 trial
showing 39 Gy in 13 fractions with a boost of 9 Gy in three
fractions delivered in 3.2 weeks to be effective and toler-
able [12].
In synopsis a boost of 9-12 Gy applied in our study to ac-
count for positive resection status seems to be safe and ef-
fective. This is a new aspect as the above mentioned
randomized studies did not apply any boost or only in part
of the cohort with single doses of 2.0 Gy. Lacking high level
evidence the American Society for Radiation Oncology
concluded that the boost indication is not clearly definable
in hypofractionation of breast cancer [17]. However, boost
RT is proven to have a benefit in conventional fractionated
breast RT with an increase in local control from 89.8% to
92.8% [18]. Together with Kim et al. we showed a higher
fractionated boost to be safe and effective in hypofractio-
nated breast RT with no substantial compromise in cos-
metic outcome. In contrast to a conventionally fractionated
boost the benefit of shorter overall treatment time is still
given.
Logistic regression analyses did not reveal any correl-
ation of acute or late effects and isodose levels, PTVs of
breast and boost or boost dose (9 Gy vs. 12 Gy). This may
confirm our treatment approach with electron boost and
two boost dose levels to be well tolerated after an inter-
mediate FU time assessed in a limited cohort with few
events (n individuals = 57 at 2 years and n = 25 at 4 years).
Further prospective data on accelerated hypofractio-
nated breast RT especially in terms of boost regimes,
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application of chemotherapy and different tumor stages
is needed.
Conclusion
An accelerated START A regime of 41.6 Gy applying 4
fractions of 3.2 Gy/week plus a boost dose of 3-4 frac-
tions of 3 Gy on day 5 results in a very satisfying tumor
control and cosmesis after a median follow up of 28
months (range 12-56).
Competing interests
There are no conflicts of interest to declare.
Authors’ contribution
SJ drafted the text and tables, and created the Excel data set together with
DW. CL/GS/CG designed the prospective evaluation forms/questionnaires.
The dose volume analysis was performed by TS/SV/SL. CG and GS initiated
and guided the project and reviewed of the manuscript. All authors read
and approved the final manuscript.
Received: 12 December 2013 Accepted: 12 July 2014
Published: 24 July 2014
References
1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R,
Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y:
Effects of radiotherapy and of differences in the extent of surgery for early
breast cancer on local recurrence and 15-year survival: an overview of the
randomised trials. Lancet 2005, 366(9503):2087–106.
2. Sautter-Bihl ML, Sauer R: Once more confirmed: adjuvant radiotherapy
and improved local control provide a significant survival benefit for
early breast cancer patients. Strahlenther Onkol 2006, 182(4):199–201.
3. Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W,
Harms W, Rödel C, Souchon R, Wenz F, Sauer R: One life saved by four
prevented recurrences? Update of the Early Breast Cancer Trialists
confirms: postoperative radiotherapy improves survival after breast
conserving surgery. Strahlenther Onkol 2012, 188(6):461–3.
4. Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P, Fietkau R,
Haase W, Harms W, Souchon R, Wenz F, Sauer R: DEGRO practical guidelines:
radiotherapy of breast cancer I : Radiotherapy following breast conserving
therapy for invasive breast cancer. Strahlenther Onkol 2013, 189(10):825–833.
5. Holloway CL, Panet-Raymond V, Olivotto I: Hypofractionation should be
the new ‘standard’ for radiation therapy after breast conserving surgery.
Breast 2010, 19(3):163–7.
6. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM,
Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P,
Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G,
Sydenham MA, Venables K, Yarnold JR: The UK Standardisation of Breast
Radiotherapy (START) Trial B of radiotherapy hypofractionation for
treatment of early breast cancer: a randomised trial. Lancet 2008,
371(9618):1098–107.
7. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W,
Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S,
Freeman C: Long-term results of hypofractionated radiation therapy for
breast cancer. N Engl J Med 2010, 362(6):513–20.
8. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ,
Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA,
Venables K, Bliss JM, Yarnold JR: The UK Standardisation of Breast Radiotherapy
(START) trials of radiotherapy hypofractionation for treatment of early breast
cancer: 10-year follow-up results of two randomised controlled trials. Lancet
Oncol 2013, 14(11):1086–94.
9. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J,
Bentzen SM, Yarnold JR: Effect of radiotherapy fraction size on tumour
control in patients with early-stage breast cancer after local tumour
excision: long-term results of a randomised trial. Lancet Oncol 2006,
7(6):467–71.
10. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM,
Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P,
Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S,
Sumo G, Sydenham MA, Venables K, Yarnold JR: The UK Standardisation of
Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for
treatment of early breast cancer: a randomised trial. Lancet Oncol 2008,
9(4):331–41.
11. Wiernik G, Bleehen NM, Brindle J, Bullimore J, Churchill-Davidson IF, Davidson J,
Fowler JF, Francis P, Hadden RC, Haybittle JL, Howard N, Lansley IF, Lindup R,
Phillips DL, Skeggs D: Sixth interim progress report of the British Institute of
Radiology fractionation study of 3 F/week versus 5 F/week in radiotherapy
of the laryngo-pharynx. Br J Radiol 1978, 51(604):241–50.
12. Kim JY, Jung SY, Lee S, Kang HS, Lee ES, Park IH, Lee KS, Ro J, Lee NK, Shin KH:
Phase 2 Trial of Accelerated, Hypofractionated Whole-Breast Irradiation of
39 Gy in 13 Fractions Followed by a Tumor Bed Boost Sequentially
Delivering 9 Gy in 3 Fractions in Early-Stage Breast Cancer. Int J Radiat
Oncol Biol Phys 2013, 87(5):1037–42.
13. Livi L, Meattini I, Franceschini D, Saieva C, Meacci F, Marrazzo L, Gerlain E,
Desideri I, Scotti V, Nori J, Sanchez LJ, Orzalesi L, Bonomo P, Greto D,
Bianchi S, Biti G: Radiotherapy boost dose-escalation for invasive breast
cancer after breast-conserving surgery: 2093 patients treated with a
prospective margin-directed policy. Radiother Oncol 2013, 108(2):273–8.
14. Liau SS, Cariati M, Noble D, Wilson C, Wishart GC: Audit of local recurrence
following breast conservation surgery with 5-mm target margin and
hypofractionated 40-Gray breast radiotherapy for invasive breast cancer.
Ann R Coll Surg Engl 2010, 92(7):562–8.
15. Pinnaro P, Soriani A, Landoni V, Giordano C, Papale M, Marsella A, Marucci L,
Arcangeli G, Strigari L: Accelerated hypofractionated radiotherapy as
adjuvant regimen after conserving surgery for early breast cancer:
interim report of toxicity after a minimum follow up of 3 years. J Exp Clin
Cancer Res 2010, 29:9.
16. Zygogianni A, Kouloulias V, Kyrgias G, Armpilia C, Antypas C, Theodorou K,
Kouvaris J: Comparison of two radiotherapeutic hypofractionated
schedules in the application of tumor bed boost. Clin Breast Cancer 2013,
13(4):292–8.
17. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS,
McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A, Taghian AG,
Vicini FA, White JR, Haffty BG: Fractionation for whole breast irradiation:
an American Society for Radiation Oncology (ASTRO) evidence-based
guideline. Int J Radiat Oncol Biol Phys 2011, 81(1):59–68.
18. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W,
Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC,
Pierart M, Collette L: Impact of a higher radiation dose on local control
and survival in breast-conserving therapy of early breast cancer: 10-year
results of the randomized boost versus no boost EORTC 22881-10882
trial. J Clin Oncol 2007, 25(22):3259–65.
doi:10.1186/1748-717X-9-165
Cite this article as: Janssen et al.: Hypofractionated radiotherapy for
breast cancer acceleration of the START A treatment regime:
intermediate tolerance and efficacy. Radiation Oncology 2014 9:165.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Janssen et al. Radiation Oncology 2014, 9:165 Page 6 of 6
http://www.ro-journal.com/content/9/1/165
